← Leaderboards
Maria F Lopes-Virella
Medical University Of South Carolina
$3,980,090
Attributed
$5,005,932
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–18$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$11,997,085 · 6
VA$0 · 1
By mechanism
P01$7,269,178 · 2
R01$4,713,195 · 3
M01$14,712 · 1
I01$0 · 1
Top collaborators
- Richard Louis Klein5 shared
Most similar at Medical University Of South Carolina
Same institution · by research overlap
- Gary S. Gilkeson$15,374,032
- Xian Zhang$1,937,483
- Francis G Spinale$19,686,300
- Samar M Hammad$1,781,348
- Juan Carlos Q. Velez$803,454
Others in their field
Top investigators on “Diabetes Mellitus”
- Jeffrey P Krischer · University Of South Florida$608,226,434
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$177,347,135
- John M Lachin · George Washington University$155,262,668
- David M Nathan · Massachusetts Institute Of Technology$142,806,023
- Judith S Hochman · New York University School Of Medicine$100,149,457
- Jose A Luchsinger · Columbia University Health Sciences$75,551,718
Research focus
Diabetes MellitusSamplingCohortComplications Of Diabetes MellitusHigh RiskInflammationPlayMacrophagePredictive ValueLeadInsulin-Dependent Diabetes MellitusGlycemic ControlLipoproteinsPlasmaBlood VesselsDiabetic AngiopathyDisease ProgressionEndothelial CellsRisk FactorsLipidsCellsFollow-UpClinical ResearchLow-Density Lipoproteins
Grant awards (26)
Role of Sphingolipids in the Development of Diabetic Nephropathy$402,716
R01 · FY2018 · DK · contact PI
Role of Sphingolipids in the Development of Diabetic Nephropathy$402,716
R01 · FY2017 · DK · contact PI
Lipoproteins and Inflammation in the Development of Diabetic Complications$0
I01 · FY2017 · VA · contact PI
Role of Sphingolipids in the Development of Diabetic Nephropathy$402,716
R01 · FY2016 · DK · contact PI
Lipoproteins and Inflammation in the Development of Diabetic Complications$0
I01 · FY2016 · VA · contact PI
Role of Sphingolipids in the Development of Diabetic Nephropathy$402,716
R01 · FY2015 · DK · contact PI
Lipoproteins and Inflammation in the Development of Diabetic Complications$0
I01 · FY2015 · VA · contact PI
Role of Sphingolipids in the Development of Diabetic Nephropathy$440,821
R01 · FY2014 · DK · contact PI
Lipoproteins and Inflammation in the Development of Diabetic Complications$0
I01 · FY2014 · VA · contact PI
Biomarkers of Vascular Disease Progression in Type 1 Diabetes Mellitus$395,079
R01 · FY2011 · DK · contact PI
Biomarkers of Vascular Disease Progression in Type 1 Diabetes Mellitus$506,160
R01 · FY2010 · DK · contact PI
Biomarkers of Vascular Disease Progression in Type 1 Diabetes Mellitus$441,115
R01 · FY2009 · DK · contact PI
Biomarkers of Vascular Disease Progression in Type 1 Diabetes Mellitus$410,125
R01 · FY2009 · DK · contact PI
Biomarkers of Vascular Disease Progression in Type 1 Diabetes Mellitus$443,996
R01 · FY2008 · DK · contact PI
Markers and Mechanisms of Vascular Disease in Diabetes$1,894,024
P01 · FY2005 · HL
MODIFIED LDL, AUTOIMMUNITY AND VASCULAR DISEASE IN DIABETES$73,467
P01 · FY2005 · HL
MARKERS AND MECHANISMS OF MACROVASCULAR DISEASE IN IDDM$612
M01 · FY2005 · RR
Markers and Mechanisms of Vascular Disease in Diabetes$1,849,846
P01 · FY2004 · HL
Markers and Mechanisms of Macrovascular Disease in IDDM$14,100
M01 · FY2004 · RR
Markers and Mechanisms of Vascular Disease in Diabetes$1,807,267
P01 · FY2003 · HL
Markers and Mechanisms of Vascular Disease in Diabetes$1,440,016
P01 · FY2002 · HL
MODIFIED LDL, AUTOIMMUNITY AND VASCULAR DISEASE IN DIABETES$73,467
P01 · FY2002 · HL
MACROPHAGE ACTIVATION AND LIPOPROTEIN METABOLISM$235,954
R01 · FY2001 · HL
MODIFIED LDL, AUTOIMMUNITY AND VASCULAR DISEASE IN DIABETES$73,467
P01 · FY2001 · HL
MACROPHAGE ACTIVATION AND LIPOPROTEIN METABOLISM$229,081
R01 · FY2000 · HL
MODIFIED LDL, AUTOIMMUNITY AND VASCULAR DISEASE IN IDDM$57,624
P01 · FY2000 · HL